Clinical Trials Logo
  1. Home
  2. Acute Chest Syndrome
  3. NCT03498105

Utility of the Cardiac Electrical BiomarkerDisease — VECTRA  

Acute Chest Syndrome Clinical Trial

Official title:
Utility of the Cardiac Electrical Biomarker in Patients With Ischaemic Heart Disease

Clinical Trial Summary

This project is aiming to identify the diagnostic utility CEB (Cardiac Electrical Biomarker) in patients who are undergoing cardiac investigations.

Clinical Trial Description

This project is aiming to identify the diagnostic utility of an ECG derived measurement by a Medical device (Vectraplex by VectraCor ltd) in patients who are undergoing cardiac investigations. This technology is based on the principle of vector ECG and an analysing system that computes a composite score termed a Cardiac Electrical Biomarker (CEB TM). CEB has been validated in the detection of STEMI with high sensitivity and specificity in the detection ECG changes characteristic to STEMI. The CEB may be a more accurate way of identifying heart injury and causes of chest pain compared to standard tests, which could lead to faster diagnosis and treatment of these patients. The diagnostic utility of the CEBTM in the following: 1. Acute chest pain assessment in the A&E department. 2. Acute chest pain assessment in the Primary Care Surgery. 3. Performance of CEB during inducible ischaemia in patients with stable angina 4. Performance of CEB during acute ischaemia in patients undergoing percutaneous coronary intervention (PCI) 5. Performance of CEB in patients undergoing cardio-toxic treatment ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03498105
Study type Observational
Source Milton Keynes University Hospital NHS Foundation Trust
Contact Antoanela Colda
Phone 0044 1908 995136
Email antoanela.colda@mkuh.nhs.uk
Status Recruiting
Phase
Start date May 22, 2017
Completion date June 30, 2023
View Details
See also
  Status Clinical Trial Phase
Withdrawn NCT02630394 - A Pilot Study of Azithromycin Prophylaxis for Acute Chest Syndrome in Sickle Cell Disease Phase 1
Active, not recruiting NCT04170348 - Daily Vitamin D for Sickle-cell Respiratory Complications Phase 2
Terminated NCT02098993 - Feasibility Study of Unfractionated Heparin in Acute Chest Syndrome Phase 2
Not yet recruiting NCT06214845 - Early-goal Directed Automated Red Blood Cell Exchange for Acute Chest Syndrome in Sickle Cell Disease N/A
Completed NCT02187445 - Inhaled Corticosteroid Use to Prevent Acute Chest Syndrome Recurrence in Children Between 1 and 4 With Sickle Cell Disease: a Feasibility Trial Phase 1
Completed NCT01089439 - Nitric Oxide Therapy for Acute Chest Syndrome in Sickle Cell Disease Children Phase 2
Completed NCT03919266 - Combined Use of a Respiratory Broad Panel Multiplex PCR and Procalcitonin to Reduce Antibiotics Exposure in Hospitalized Sickle-cell Adults With Acute Chest Syndrome. N/A
Terminated NCT01589926 - Bi-Level Positive Airway Ventilation for Acute Chest Syndrome N/A
Completed NCT01041339 - ST Elevation in Acute Chest Pain; Could Measurement of Lipoprotein-associated Phospholipase A2 (Lp-PLA2) be Helpful to the Clinician? N/A
Completed NCT03250585 - sPLA2 in EBC During Acute Chest Syndrome
Completed NCT03805581 - Defibrotide in Sickle Cell Disease-Related Acute Chest Syndrome Phase 2
Recruiting NCT03032055 - Validation of a Predictive Score of Acute Chest Syndrome
Terminated NCT03820466 - Effect of Platelet Inhibition and / or Lipid Lowering in Non-ACS-patients With Positive Troponin Phase 3
Completed NCT00748423 - Effect of Inhaled Nitric Oxide in Acute Chest Syndrome (INOSTA Study) Phase 2/Phase 3
Completed NCT00434473 - IMPACTS Trial: Investigation of the Modulation of Phospholipase in Acute Chest Syndrome Phase 2
Completed NCT02580773 - Therapeutic Anticoagulation Strategy for Acute Chest Syndrome Phase 3
Completed NCT01443728 - Vitamin D for Sickle-cell Respiratory Complications Phase 2
Recruiting NCT05640271 - Tocilizumab for Acute Chest Syndrome Phase 2